These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 30152284)
1. Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update. Khan MA; Alam Q; Haque A; Ashafaq M; Khan MJ; Ashraf GM; Ahmad M Curr Neuropharmacol; 2019; 17(3):232-246. PubMed ID: 30152284 [TBL] [Abstract][Full Text] [Related]
2. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Landreth G; Jiang Q; Mandrekar S; Heneka M Neurotherapeutics; 2008 Jul; 5(3):481-9. PubMed ID: 18625459 [TBL] [Abstract][Full Text] [Related]
3. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. Jiang Q; Heneka M; Landreth GE CNS Drugs; 2008; 22(1):1-14. PubMed ID: 18072811 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. Mandrekar-Colucci S; Karlo JC; Landreth GE J Neurosci; 2012 Jul; 32(30):10117-28. PubMed ID: 22836247 [TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis. Liu J; Wang LN; Jia JP Drugs Aging; 2015 Jan; 32(1):57-65. PubMed ID: 25504005 [TBL] [Abstract][Full Text] [Related]
8. [Alzheimer's disease]. Hanyu H; Sato T Nihon Rinsho; 2010 Feb; 68(2):330-4. PubMed ID: 20158105 [TBL] [Abstract][Full Text] [Related]
9. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. Watson GS; Craft S CNS Drugs; 2003; 17(1):27-45. PubMed ID: 12467491 [TBL] [Abstract][Full Text] [Related]
10. An in-silico approach: identification of PPAR-γ agonists from seaweeds for the management of Alzheimer's Disease. Kotha S; B S; Kulkarni VM; S RS; B HK; R H J Biomol Struct Dyn; 2021 Apr; 39(6):2210-2229. PubMed ID: 32216605 [TBL] [Abstract][Full Text] [Related]
11. A review on the development in the field of NIDDM based thiazolidinedione PPARγ agonists. Banerjee PS; Samanta S Mini Rev Med Chem; 2013 Apr; 13(5):706-12. PubMed ID: 22512587 [TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Cho N; Momose Y Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761 [TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Touyz RM; Schiffrin EL Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs. Schinner S; Krätzner R; Baun D; Dickel C; Blume R; Oetjen E Br J Pharmacol; 2009 Jul; 157(5):736-45. PubMed ID: 19338578 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. Landreth G Curr Alzheimer Res; 2007 Apr; 4(2):159-64. PubMed ID: 17430241 [TBL] [Abstract][Full Text] [Related]
17. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties. Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587 [TBL] [Abstract][Full Text] [Related]
18. Pioglitazone for the treatment of Alzheimer's disease. Galimberti D; Scarpini E Expert Opin Investig Drugs; 2017 Jan; 26(1):97-101. PubMed ID: 27885860 [TBL] [Abstract][Full Text] [Related]